Global Generative Artificial Intelligence (AI) In Pharmaceutical Market Set For 31.1% Growth, Reaching $5.4 Billion

December 09, 2024 03:15 PM AEDT | By EIN Presswire
 Global Generative Artificial Intelligence (AI) In Pharmaceutical Market Set For 31.1% Growth, Reaching $5.4 Billion
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, December 9, 2024 /EINPresswire.com/ -- The Business Research Company’s Early Year-End Sale! Get up to 30% off detailed market research reports—limited time only!

The generative artificial intelligence AI in the pharmaceutical market has witnessed exponential growth in recent years. It is projected to grow from $1.41 billion in 2023 to a promising $1.85 billion in 2024, showcasing a compound annual growth rate CAGR of 31%. The surge in the previous period can be credited to the expansion in computational power, the prominence of big data in healthcare and pharmaceuticals, booming research and development investment, amplified data quality, and seamless integration and spread of cloud computing.

Interested in the Detailed Market Landscape of the Generative Artificial Intelligence AI In Pharmaceutical Sector?

The predictive trajectory of the generative AI in the pharmaceutical market suggests exponential growth in the forthcoming years. It is slated to reach a staggering $5.47 billion in 2028, at a compound annual growth rate CAGR of 31.1%. This sustainable growth in the projection period can be linked to a renewed emphasis on early disease detection, robust regulatory support, and guidelines combined with an enhanced computational power, surge in drug development costs, and increased data availability. Notable trends gating the forecast period include a seamless blend of blockchain and AI, advanced data integration, improved disease prognosis, automated drug repurposing, real-time clinical trial optimization.

Pre-book the report for a swift delivery:
https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-pharmaceutical-global-market-report

What's Driving the Generative Artificial Intelligence AI In Pharmaceutical Market Growth?

An overarching emphasis on personalized medicine is anticipated to boost the market for generative AI in pharmaceuticals. Personalized Medicine customizes medical treatment to the individual traits, requirements, and predilections of patients, leveraging genetic, environmental, and lifestyle factors. The focus on personalized medicine is gathering pace due to advancements in genetic research and technology, enabling more precise and effective treatments individualized for each patient. For instance, in February 2024, a US-based non-profit organization, Personalized Medicine Coalition, relayed that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to a mere six in 2022. Such trends demonstrate the vital role of personalized medicine in driving the growth of generative AI in the pharmaceutical market.

Who Are the Top Players Boosting the Generative Artificial Intelligence AI In Pharmaceutical Market?

Key global leaders stimulating the generative artificial intelligence AI in pharmaceutical market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Fujitsu Limited, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., NVIDIA Corporation, Conduent Incorporated, XtalPi Inc., Insilico Medicine Inc., Numerate Inc., Atomwise Inc., and BenevolentAI Limited.

How is Technology Reshaping the Generative Artificial Intelligence AI In Pharmaceutical Landscape?

Trendsetting companies operating in the generative AI in pharmaceutical market are venturing into new products, such as AI healthcare microservices, to streamline drug discovery processes. For instance, in March 2024, Nvidia Corporation launched generative AI microservices. These present advanced imaging, natural language, and speech recognition, along with digital biology capabilities, thereby enhancing drug discovery and genomic workflows.

How is the Generative Artificial Intelligence AI In Pharmaceutical Market Structured?

The generative artificial intelligence AI in the pharmaceutical market report encapsulates the market's segmentation:
1 By Type: Small Molecule, Large Molecule
2 By Technology: Deep Learning, Natural Language Processing, Querying Method, Context-Aware Processing, Other Technologies
3 By Application: Clinical Trial Research, Drug Discovery, Research And Development, Other Applications

Dive Into Detailed Insights of the Global Generative Artificial Intelligence (AI) In Pharmaceutical Market with a Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19474&type=smp

Regional Dissection of the Generative Artificial Intelligence AI In Pharmaceutical Market

North America led the generative artificial intelligence AI in pharmaceutical market in 2023. The encompassed regions in the report comprise Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:
Generative AI In Gaming Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/generative-ai-in-gaming-global-market-report
Generative AI Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/generative-ai-global-market-report
Generative Artificial Intelligence (AI) in Sports Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-sports-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Connect with us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.